The study examined more than 3,000 U.S. patients who recently received a cancer diagnosis and were screened for hepatitis B, hepatitis C and HIV.
Although the patients’ infection rates were similar to those in the general population, 87 percent of patients with past hepatitis B; 42 percent of patients with chronic hepatitis B; and 31 percent of those with hepatitis C infections had not been diagnosed, the study found.
“Screening patients with newly diagnosed cancer to identify hepatitis B virus and hepatitis C virus infection before starting treatment may be warranted to prevent viral reactivation and adverse clinical outcomes,” the researchers concluded.
More articles on clinical leadership and infection control:
Australian researcher develops antibiotic to fight C. diff
WHO official: Congo’s Ebola outbreak will last 6 more months
Senators seek info on universal flu vaccine research: 4 takeaways
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.